Filing Details

Accession Number:
0000950170-23-018401
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-05 18:00:56
Reporting Period:
2023-05-03
Accepted Time:
2023-05-05 18:00:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1840229 Mink Therapeutics Inc. INKT Biological Products, (No Disgnostic Substances) (2836) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1098972 Agenus Inc 3 Forbes Road
Lexington MA 02421
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-05-03 128,689 $1.08 21,473,374 No 4 P Direct
Common Stock Acquisiton 2023-05-04 21,473 $1.22 21,494,847 No 4 P Direct
Common Stock Acquisiton 2023-05-05 100,000 $0.95 21,594,847 No 4 P Direct
Common Stock Acquisiton 2023-05-05 200 $1.25 21,595,047 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $0.9144 to $1.20).
  2. Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
  3. Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $1.20 to $1.25).
  4. On May 5, 2023, Agenus purchased 100,000 shares of MiNk Therapeutics, Inc. common stock from Garo Armen, Agenus's Chairman and CEO, at the same price he paid to acquire the shares on May 2, 2023. The acquisition price represents a 40% discount to the market price as of today's market close.